Oxford Immunotec starts offering for ordinary shares
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Oxford Immunotec Global PLC will sell 2.5 million ordinary shares in an underwritten public offering.
The company has granted the underwriter an option to buy up to 375,000 additional shares.
Oxford Immunotec intends to use the net proceeds from the offering for working capital and general corporate purposes.
BTIG LLC is acting as sole underwriter for the offering.
